Novartis, Tanabe LFA-1 deal

Novartis (NVS; SWX:NOVN) received an exclusive license in the U.S., Europe and elsewhere to develop and market Tanabe's leukocyte function-associated antigen-1 ( LFA-1) antagonists to treat inflammato...